SAN DIEGO--(BUSINESS WIRE)--TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that Skyline Diagnostics BV, a company which develops and commercializes diagnostic microarrays for oncology, has licensed its NPM1 technology to be included in one of its microarray products. Skyline Diagnostics plans to initially offer this product as a laboratory testing service in Europe and will eventually expand this testing service to markets outside of Europe.
